PCSK9 Inhibitors in the Progression of Aortic Stenosis
PCSK9 Inhibitors in the Progression of Aortic Stenosis
Investigators plan evaluate whether PCSK9 inhibitors, a medication that can lower
 lipoprotein(a) and control dyslipidemia, can inhibit the progression of aortic stenosis,
 through a randomized controlled trial.
Aortic valve disease is the most common form of heart valve disease and is a major burden to
 society. Aortic valve disease is also expected to become more prevalent with the aging. Among
 aortic diseases, 'aortic stenosis (AS)', which is a narrowing of the aortic valve, and leads
 to symptoms of heart failure and sometimes death.

 For treatment of AS, the valve in replaced in a surgical to percutaneous method. Regardless
 of the method, valve replacement has its potential costs and complications that is an
 important issue that needs to be solved. Therefore, controlling the progression of AS and
 increasing the efficacy of medical therapy before valvular replacement is needed, is an
 important medico-social problem.

 Regarding the pathophysiology of AS, an elevation of lipoprotein(a) and dyslipidemia have
 been reported to be associated with the progression of cardiovascular calcification.

 PCSK9 inhibitors, which is a medication that can control both lipoprotein(a) and dyslipidemia
 may be a effective medication to control the progression of AS.

 Therefore, investigators will perform a randomized control trial, to compare the effect of
 PCSK9 inhibitors vs. placebo in its influence to AS progression.
Inclusion Criteria:

 1. The patient agrees to participate in this study by signing the informed consent form.
 Alternatively, a legally authorized patient representative may agree to the patient's
 participation in this study and sign the informed consent form.

 2. The patient has a working diagnosis of aortic stenosis (mild to moderate), and has
 fair treatment compliance.

 Exclusion Criteria:

 1. Age under 19 years old

 2. Hypersensitivity to PCSK9 inhibitor

 3. LDL cholesterol < 70mg/dL at baseline

 4. Poor treatement compliance (The patient will need to visit the out-patient clinic
 every 2-weeks for medication)

 5. Positive pregnancy test or is known to be pregnant

 6. Any other reason the investigator deems the subject to be unsuitable for the study
 (e.g., Active malignant tumor, Any life-threatening condition with life expectancy
 less than 6months, etc.)

 7. Any clinically significant abnormality identified at the screening visit, physical
 examination, laboratory tests, or electrocardiogram which, in the judgment of the
 investigator, would preclude safe completion of the study